Glimbax

Glimbax is a medicinal product that contains the active ingredient diclofenac, a non‑steroidal anti‑inflammatory drug (NSAID). It is supplied in an oromucosal dosage form, though the specific strength is not disclosed in the available data. Marketed in the European Union, Glimbax belongs to the analgesic/anti‑inflammatory therapeutic class and works by inhibiting cyclooxygenase enzymes to reduce prostaglandin‑mediated inflammation and pain for short‑term management of mild to moderate musculoskeletal discomfort.

Glimbax is indicated for the symptomatic relief of pain and inflammation associated with several musculoskeletal conditions.

- Acute pain from minor injuries such as sprains, strains, or bruises. - Chronic osteoarthritis pain where oral NSAIDs are appropriate. - Post‑operative dental or oral surgery discomfort. - Inflammatory conditions of the temporomandibular joint. - Short‑term management of low‑grade back pain when a topical or oromucosal option is preferred.

The safety profile of Glimbax reflects that of other diclofenac preparations, with side effects ranging from mild and transient to rare but serious.

Common: - Gastrointestinal discomfort such as dyspepsia, nausea, or mild abdominal pain. - Headache or transient dizziness. - Mild skin redness or irritation at the site of administration. - Increased urinary frequency or mild diuresis.

Serious: - Signs of gastrointestinal bleeding (e.g., black stools, vomiting blood). - Elevated liver enzymes indicating hepatic irritation. - Severe skin reactions such as Stevens‑Johnson